Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JKN2401 in moderate-to-severe COPD
NCT07330310Phase 3Not yet recruiting
- Sponsor
- Joincare Pharmaceutical
- Start
- Mar 2026
- Primary completion
- Sep 2027
- Modality
- Monoclonal Antibodies
01
Overview
A Phase 3 trial of JKN2401 in chronic obstructive pulmonary disease (COPD), sponsored by Joincare Pharmaceutical. Planned start Mar 2026; status: not yet recruiting.
02
Drugs
JKN2401
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT07330310.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07330310.